NUR 635 Topic 1 pharmacokinetics application example

Advanced Pharmacology Grand Canyon University Free custom sample in 24 to 48h

This NUR 635 Topic 1 sample paper answers a valproate dose question for Mrs. E., a composite 71-year-old in intensive care for sepsis with a low total level and an albumin of 2.2. It was written for GCU NUR 635, Advanced Pharmacology, catalog code NUR-635, a course in Grand Canyon University's MSN. Absorption and distribution explain the oral route and loading. Metabolism, clearance and half-life are worked through with the arithmetic shown. Protein binding is the variable that changes everything here. Pharmacodynamics is kept separate from kinetics. The answer is not to raise the dose, because a free level of 14 mg/L is already high, after Drisaldi and colleagues, Riker and colleagues and Rowland and Tozer.

CourseNUR 635 Advanced Pharmacology
TopicTopic 1
Paper typePharmacokinetic dosing analysis
LengthAbout 990 words, 4 pages
FormatAPA 7 student paper
SchoolGrand Canyon University (GCU)
ProgramMSN
UpdatedOctober 2026

Free sample paper for NUR 635 Topic 1

1

A Low Total Level, a High Free Level: Answering a Valproate Dose Question in a 71-Year-Old Woman With an Albumin of 2.2

[Author Name]

College of Nursing and Health Care Professions, Grand Canyon University

NUR-635: Advanced Pharmacology

Topic 1 Assignment

[Instructor Name]

January 14, 2030

The organization, setting and figures below are a composite written as a model document. No real employer, client, colleague or patient is described.

What this page is doingThe title states the dosing question as the two numbers that pull against each other, so every pharmacokinetic concept that follows has a decision to answer. The patient is a composite written for teaching.
2

A Low Total Level, a High Free Level: Answering a Valproate Dose Question in a 71-Year-Old Woman With an Albumin of 2.2

The Dosing Question

Mrs. E., a composite 71-year-old woman weighing 58 kg, has spent three days in intensive care being treated for sepsis. On day 1 she developed focal status epilepticus, which stopped after lorazepam and an intravenous loading dose of valproate, followed by 500 mg intravenously every 8 hours. Her serum albumin is 2.2 g/dL, her liver enzymes are mildly raised and her kidney function is normal. Continuous electroencephalography has shown no seizures for 48 hours. This morning's trough total valproate concentration is 44 mg/L, below the laboratory's reference range of 50 to 125 mg/L, and the team proposes increasing the dose to 750 mg every 8 hours. A free valproate concentration drawn at the same time is 14 mg/L, against a free reference range of 5 to 17 mg/L. The question is whether to increase the dose.

Absorption and Distribution: Route and Loading

Valproate is almost completely absorbed when taken by mouth and undergoes little first-pass metabolism, so its oral bioavailability is close to 100 percent. That is why, when Mrs. E. can swallow, her intravenous dose can be converted to an oral dose milligram for milligram. The contrast with a drug such as morphine, most of which is metabolized by the liver on its first pass from the gut, shows what first-pass metabolism does: for such drugs the oral dose must be several times the intravenous dose to deliver the same amount to the circulation.

Volume of distribution explains why she received a loading dose at all. It is the apparent volume into which a drug would have to be dissolved to give the measured plasma concentration, and the dose needed to reach a target concentration at once is that volume multiplied by the target (Rowland & Tozer, 2011). Without a loading dose, concentrations build up over four to five half-lives, far too slowly for status epilepticus. Valproate's volume of distribution is small, because it is highly bound to albumin and stays mostly in plasma, so a modest loading dose raises concentrations quickly.

What this page is doingBioavailability and volume of distribution are each tied to a decision in this patient: the intravenous-to-oral conversion and the reason a loading dose was given. Neither is left as a definition.
3

Metabolism, Clearance and Half-Life, With the Arithmetic

Valproate is cleared almost entirely by the liver, through conjugation and oxidation. Its half-life in healthy adults is roughly 9 to 16 hours and tends to be longer in older adults and in liver dysfunction. Taking 15 hours as a reasonable estimate for Mrs. E., steady state, reached after about four to five half-lives, arrives after 60 to 75 hours. Her day 3 trough, drawn about 64 hours after maintenance dosing began, is therefore close to steady state and can be interpreted. If valproate were stopped, the same arithmetic governs washout: after 60 to 75 hours, about 94 to 97 percent would be gone, which matters if a drug interaction or an adverse effect required stopping it.

The Patient Variable That Changes Everything: Protein Binding

In healthy adults at usual concentrations, about 90 percent or more of valproate is bound to albumin, so only 5 to 10 percent is free. Only free drug crosses into the brain and acts on neurons, and only free drug is available to the liver's enzymes. Most laboratories measure total drug, bound plus free, and the total reference range assumes normal binding. When albumin is low, when uremia or other drugs displace valproate from albumin, or when concentrations are high enough to saturate binding sites, the free fraction rises. In a series of intensive care patients with albumin below 4 g/dL, no patient had a free fraction in the usual 5 to 10 percent range; the median was 48 percent, and total and free concentrations correlated poorly (Riker et al., 2017).

For a drug like valproate, with low hepatic extraction and high binding, a fall in binding lowers the total concentration at steady state but leaves the free concentration, the one that matters, largely unchanged, because the liver clears more drug when more of it is free. Mrs. E.'s numbers show exactly this: a total of 44 mg/L and a free concentration of 14 mg/L give a free fraction of about 32 percent, three to six times normal. Her total level is low because her binding is low, not because she has too little active drug. Formulas that estimate free concentration from total concentration and albumin are not a safe substitute, since they underestimated measured free concentrations in almost all discordant cases in one analysis (Drisaldi et al., 2019).

What this page is doingProtein binding is applied to this patient's albumin and this drug's clearance, and the free fraction is calculated from her own results. The highlighted sentence states the principle that turns the two numbers into a decision.
4

Pharmacodynamics, Kept Separate

Everything above describes what the body does to valproate. What valproate does to the body is a separate question with its own evidence. Pharmacodynamically, the drug has done what it was given for: continuous monitoring shows no seizures for 48 hours. The adverse effects that matter here, sedation, hyperammonemia, thrombocytopenia and liver injury, also belong to pharmacodynamics, and several are more likely when free concentrations are high. Her platelets and ammonia will be checked, and her level of alertness assessed, alongside the free concentration.

Answering the Question

The dose should not be increased. Her free valproate concentration of 14 mg/L is already in the upper part of its reference range, and her seizures are controlled. Increasing the dose by 50 percent, from 1,500 to 2,250 mg a day, would raise the free concentration at least in proportion, to about 21 mg/L or more because binding saturates at higher concentrations, above the range and into the zone where sedation and hyperammonemia become more likely, while treating a low total level that reflects binding rather than drug effect. The plan is to continue 500 mg every 8 hours, repeat free concentrations twice a week while albumin remains low, check ammonia and platelets, and convert to an equal oral dose when she can swallow. If her albumin recovers, her total concentration will rise without any dose change, and it should then be interpreted against the total range again.

References

Drisaldi, A., Weeda, E., Neyens, R., Orvin, N., Bonilha, L., Campbell, Z., & Bohm, N. (2019). Accuracy of valproic acid concentration correction based on serum albumin. Neurocritical Care, 30(2), 301-306. https://doi.org/10.1007/s12028-018-0627-4

Riker, R. R., Gagnon, D. J., Hatton, C., May, T., Seder, D. B., Stokem, K., & Fraser, G. L. (2017). Valproate protein binding is highly variable in ICU patients and not predicted by total serum concentrations: A case series and literature review. Pharmacotherapy, 37(4), 500-508. https://doi.org/10.1002/phar.1912

Rowland, M., & Tozer, T. N. (2011). Clinical pharmacokinetics and pharmacodynamics: Concepts and applications (4th ed.). Lippincott Williams & Wilkins.

What the NUR 635 Topic 1 instructions ask for

Topic 1 in NUR-635 sets a dosing question that pharmacokinetic principles must settle in a specific patient. Strong papers state the question first and then work through absorption, distribution, metabolism and elimination as they bear on that question rather than as a textbook survey. Students should show the arithmetic for half-life, time to steady state or loading where it matters, identify the patient variable that changes the usual answer, such as low albumin for a highly bound drug, and keep pharmacodynamics in its own section so effect is not confused with concentration. The paper should end with a direct answer to the question asked and the monitoring that would show whether the answer was right, with levels interpreted in light of the patient's binding and clearance rather than against the usual range alone.

How the NUR-635 Topic 1 example is put together

The finished example puts every concept to work on a question. Half life is used to calculate when steady state arrives and how long clearance takes after stopping, which is what a prescriber needs it for. First pass metabolism explains why an oral dose differs from an intravenous one for a specific drug. Protein binding appears where it matters clinically, in a patient whose albumin is low. Volume of distribution explains why a loading dose exists at all. Pharmacodynamics is kept separate, so what the body does to the drug and what the drug does to the body are not blurred. Every parameter in the example ends in a dosing decision rather than a definition.

Reading the NUR 635 Topic 1 rubric

Faculty reward kinetics applied to one question. An Excellent analysis opens with whether to raise valproate in a 71-year-old with an albumin of 2.2, then works through absorption, clearance and half-life with the arithmetic shown, using Rowland and Tozer. Credit goes to identifying protein binding as the variable that reverses the usual answer, citing Drisaldi and colleagues and Riker and colleagues. The rubric values pharmacodynamics kept separate. Top marks go to a direct answer, do not increase the dose, because the free level of 14 mg/L is already high.

Common NUR 635 Topic 1 mistakes, and how to avoid them

Definitions offered where applications were wanted are the weakness this topic is built to catch, and a paper explaining what half life means without using it demonstrates reading rather than prescribing. A second shortfall is kinetics and dynamics blurred together, which produces confused reasoning about why a dose change did not produce the expected effect. Papers lose marks for parameters described in general rather than for a named drug, since the numbers only become useful when attached to something specific. Ignoring the patient variables that alter clearance leaves a calculation valid only for a healthy adult. Arithmetic that does not work is penalized directly in a course where dosing depends on it.

Get an NUR-635 Topic 1 example written to your instructions

Send the NUR-635 Topic 1 instructions and the rubric posted in your classroom, with the drug or case your section assigned. We write a custom example to those criteria, with a dosing question opening the paper, half life applied to steady state and washout, and every parameter ending in a decision, in 24 to 48 hours. The first is free.

More NUR 635 papers and MSN samples

NUR 635 Topic 1 questions, answered

How do I use half life rather than define it?

Answer the two questions it exists for. Steady state arrives after roughly four to five half lives of consistent dosing, and a drug is substantially cleared after the same span once stopped. That tells you when to assess whether a dose is working, when a level is worth checking, and how long to wait before starting something that would interact. Those are prescribing decisions rather than facts.

What is the practical difference between kinetics and dynamics?

Kinetics determines how much drug is at the site and when; dynamics determines what happens once it is there. If a patient is not responding, kinetics asks whether enough drug arrived and dynamics asks whether the receptor response is what you expected. Confusing the two produces dose increases where a different agent was needed, which is why the course separates them from the start.

When does protein binding actually matter?

When it changes and when the drug is highly bound with a narrow margin between effect and harm. In a patient with low albumin, a highly bound drug has more free fraction available, so a total level can look acceptable while the active portion is not. For most drugs it is a background property; for a few it changes what a reported level means.

Where can I find a free NUR 635 Topic 1 sample paper?

The analysis for NUR 635 Topic 1 covers the dosing question, absorption and distribution, metabolism, clearance and half-life with arithmetic, protein binding, pharmacodynamics and the answer. Send your NUR 635 Topic 1 prompt and a paper follows free.

Why measure a free level in NUR 635 Topic 1?

Because with an albumin of 2.2, more valproate is unbound, so a low total level can hide a free concentration that is already high enough to cause toxicity.